Louis Tamayo serves as Chief Financial Officer at Lexeo Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for genetically defined cardiovascular and neurodegenerative diseases. Appointed in 2023, Tamayo oversees all aspects of the company's financial strategy, including capital markets activities, financial planning and analysis, treasury operations, and investor relations. His leadership has been instrumental in securing funding to support Lexeo's pipeline advancement, including pivotal clinical trials and regulatory milestones. With more than 20 years of experience in biopharmaceutical finance, Tamayo previously served as CFO at Passage Bio, where he led financial operations through a period of rapid clinical development and strategic pivots amid challenging market dynamics. Earlier, at Spark Therapeutics—a pioneer in gene therapy—he held roles as Vice President of Finance and Treasurer, contributing to the company's exponential growth and its landmark $4.3 billion acquisition by Roche in 2019. Tamayo began his career at McKinsey & Company as an engagement manager, advising life sciences clients on strategy and operations, and held finance positions at Alexion Pharmaceuticals and Deloitte. Tamayo's achievements include orchestrating multiple equity financings, IPO preparations, and M&A transactions totaling billions in value, earning him recognition for driving financial discipline in high-growth biotech environments. At Lexeo, he continues to fortify the balance sheet through innovative partnerships and non-dilutive funding, positioning the company for long-term success in delivering transformative therapies to patients with unmet medical needs.